SCHEMBL25182337

SCHEMBL25182337

COc1ccc(S(=O)(=O)n2cc(C=O)cc2-c2ccccc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.44
▸ PKLR P30613 2/20 0.44
▸ HTR6 P50406 6/20 0.42
▸ RAPGEF4 Q8WZA2 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ STAT3 P40763 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ELAVL1 Q15717 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25194800 0.89 GPR183 (0.39) PKMPKLRHTR6RAPGEF4ALDH1A1
SCHEMBL25201078 0.87 KDM4E (0.48) HTR6RAPGEF4ALDH1A1L3MBTL1POLB
SCHEMBL25189646 0.87 HTR6 (0.41) PKMHTR6ALDH1A1MEN1KMT2A
SCHEMBL25191142 0.86 HTR6 (0.40) HTR6MEN1KMT2A
SCHEMBL25182338 0.84 MEN1 (0.40) PKMHTR6ALDH1A1L3MBTL1MEN1
SCHEMBL1156459 0.84 ALDH1A1 (0.54) PKMPKLRHTR6RAPGEF4ALDH1A1
SCHEMBL25191377 0.84 HTR6 (0.39) HTR6RAPGEF4ALDH1A1
SCHEMBL25192716 0.83 ELAVL1 (0.40) PKMHTR6ALDH1A1MEN1KMT2A
SCHEMBL25189206 0.82 PTGS2 (0.45) PKMPKLRHTR6RAPGEF4ALDH1A1
SCHEMBL25203015 0.82 PTGS2 (0.41) HTR6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT HANA PHARM CO., LTD. (KR) 2025-02-13 — — US disclosed
EP-4434966-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT Hana Pharm. Co. Ltd. (KR) 2024-09-25 — — EP disclosed
CN-118451060-A Pyrrole derivative or pharmaceutically acceptable salt thereof and composition for preventing, improving or treating gastrointestinal diseases comprising the same as active ingredient 合娜制药株式会社 2024-08-06 — — CN disclosed
WO-2023090942-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT 하나제약 주식회사 2023-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT STOM, SI, PGC PKM 404/4885PKLR 2150/4885HTR6 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback